ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1811

The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Abstract Number: 1812

Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Abstract Number: 1813

Elucidating the Molecular Correlates of Treatment Response in Lupus Nephritis via Imaging Mass Cytometry Proteomics and Machine Learning
Abstract Number: 1814

Understanding Monocyte Derived Macrophages in the Skin of SSc Patients Through Single Cell Analysis of Blister Fluid Immune Cell Populations
Abstract Number: 1815

Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel
Abstract Number: 1816

Paracrine WNT Signaling Drives Pro-fibrotic Metabolic Activation of Systemic Sclerosis Macrophages
Abstract Number: 1817

Activated Macrophages Mediate Loss of Dermal White Adipose Tissue in Fibrotic Skin
Abstract Number: 1818

Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin
Abstract Number: 1819

Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis
Abstract Number: 1820

Disruption of Ca2+ Homeostasis and Enhanced Ca2+ Signaling in Scleroderma Fibroblasts Is Due to the Vicious Cycle Formed by Mitochondrial-derived Reactive Oxygen Species, CaMKII, and ER Extrusion Pump RYR2
Abstract Number: 1821

Single-Cell RNA SequencingBioinformatic Pipeline Optimized for Non-Coding GenesIdentified LINC01503 and MIR193-BHG as Potential Pathogenic Effectors in Systemic Sclerosis Fibroblasts
Abstract Number: 1822

Analysis of Differential Activation of Lysophosphatidic Acid Regulated Genes in Diffuse and Limited Cutaneous Systemic Sclerosis
Abstract Number: 1823

Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts
Abstract Number: 1824

Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial
Abstract Number: 1825

Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].